Incyte

Yahoo Finance • 4 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., October 08, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 22,107 shares of the Company’s common stock to 26 new employees. The... Full story

Yahoo Finance • 7 months ago

S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?

S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday? The S&P 500 index climbed to new all-time highs, rising 0.3% during Tue... Full story

Yahoo Finance • 8 months ago

Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers

Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing up 0.6% at 19,576 points and reaching new... Full story

Yahoo Finance • 8 months ago

Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings

WILMINGTON, Del., May 21, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmin... Full story

Yahoo Finance • 10 months ago

Incyte to Report First Quarter Financial Results

WILMINGTON, Del., April 11, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024. The schedule for th... Full story

Yahoo Finance • 10 months ago

12 Best S&P 500 Stocks To Buy According to Analysts

In this piece, we will take a look at the 12 best S&P 500 stocks to buy according to analysts. If you want to skip our coverage of the latest happenings surrounding one of America's most widely followed stock indexes, then you can take a l... Full story

Yahoo Finance • 10 months ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., March 29, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant... Full story

Yahoo Finance • 11 months ago

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura®) in hidradenitis suppurativa and povorcitinib (INCB54707) in prurigo nodularis Analyst and investor... Full story

Yahoo Finance • 12 months ago

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del., February 15, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 9:50 a.m. (EST) in Boston. The presentation will b... Full story

Yahoo Finance • 12 months ago

Decoding Incyte Corp (INCY): A Strategic SWOT Insight

In-depth examination of Incyte Corp's strengths, including its robust product portfolio and market leadership in Hematology/Oncology. Analysis of potential weaknesses and areas for improvement, such as reliance on key products and market c... Full story

Yahoo Finance • 12 months ago

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high. Continue reading... Full story

Yahoo Finance • last year

EVP & Chief Medical Officer Steven Stein Sells Shares of Incyte Corp (INCY)

In a recent transaction filed with the SEC, Steven Stein, EVP & Chief Medical Officer of Incyte Corp (NASDAQ:INCY), sold 7,365 shares of the company on January 3, 2024. The transaction was disclosed in a SEC Filing. Warning! GuruFocus has... Full story

Yahoo Finance • last year

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can... Full story

Yahoo Finance • last year

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are featured in the Plenary Scientific Session at... Full story

Yahoo Finance • last year

BAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd

Significant Addition to BeiGene Holdings BAKER BROS. ADVISORS LP (Trades, Portfolio), a prominent investment firm, has recently expanded its investment in BeiGene Ltd (NASDAQ:BGNE) with a substantial acquisition of shares. On November 14,... Full story

Yahoo Finance • last year

Top 20 Drug Companies in the US by Revenue

In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which d... Full story

Yahoo Finance • last year

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature the full data from AGAVE-201 evaluating axatilim... Full story

Yahoo Finance • last year

Science Magazine Recognizes Incyte as #2 "Top Employer" of 2023

WILMINGTON, Del., October 27, 2023--(BUSINESS WIRE)--Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals. Incyte rank... Full story

Yahoo Finance • last year

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing... Full story

Yahoo Finance • last year

Thérapeutique Knight annonce l’approbation de prix de Minjuvi® (tafasitamab) au Brésil

MONTRÉAL, 16 oct. 2023 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que sa société affiliée brésilienn... Full story